Downloads
Abstract
Background: The aims of our study were to investigate the toxicity of Pembrolizumab monotherapy in advanced - stage non - small cell lung cancer patients.
Methods: Clinical trial, retrospective study. From October 2017 to June 2020, we enrolled 28 advanced - stage non-small cell lung cancer patients at National Cancer hospital. All patients received pembrolizumab monotherapy as first line or later line after chemotherapy. Toxicity was determined.
Results: Toxicities appearred in 39,3% patients, most were tolerable. Immune - related adverse events (irAEs) were 10,7%, most common irAEs were hyperthyroidism (7,1%), followed by hypothyroidism (3,6%). 10,7% patients experienced AEs in hematologic system, included anemia (7,1%), neutropenia (3,6%). 21,4% patients experienced extra-hematological toxicities, 10,7% hypertransaminasemia, 3,6% hyperglycemia, 3,6% hypercreatininemie.
Conclusions: Pembrolizumab monotherapy using in advanced - stage non - small cell lung cancer is tolerable with small rate of irAEs and toxicities in other systems.
References
Bray F., Ferlay J., Soerjomataram I., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6), 394-424.
Socinski M.A., Evans T., Gettinger S., et al. (2013). Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e341S-e368S.
Forde P.M. and Ettinger D.S. (2013). Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther, 13(6), 745-758.
Herbst R.S., Baas P., Kim D.-W., et al. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet, 387(10027), 1540-1550.
Mok T.S.K., Wu Y.-L., Kudaba I., et al. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, openlabel, controlled, phase 3 trial. The Lancet, 393(10183), 1819-1830.
B S., K S., R B., et al. (2009). A Review of Human carcinogens--Part E: Tobacco, Areca Nut, Alcohol, Coal Smoke, and Salted Fish. The Lancet. Oncology, <https://pubmed.ncbi.nlm.nih. gov/19891056/>, accessed: 07/01/2020.
Reck M., Rodríguez-Abreu D., Robinson A.G., et al. (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 375(19), 1823-1833.
Trương Văn Sáng (2019) Đánh giá kết qủa điều trị phác đồ pemetrxed - carboplatin trên bệnh nhân ung thư biểu mô tuyến của phổi giai đoạn IV. Luận án tiến sĩ y học trường đại học Y Hà Nội, Hà Nội.
| Published | 07-01-2025 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 67 (2021) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.2021.67.12 | |
| Keywords | UTPKTBN giai đoạn muộn, điều trị pembrolizumab đơn chất, độc tính Advanced - stage non-small cell lung cancer, pembrolizumab monotherapy, toxicity |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2021 Journal of Clinical Medicine Hue Central Hospital